{"name":"Centre de Recherche Médicale de Lambaréné","slug":"centre-de-recherche-m-dicale-de-lambar-n","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Artefenomel-Ferroquine","genericName":"Artefenomel-Ferroquine","slug":"artefenomel-ferroquine","indication":"Treatment of uncomplicated Plasmodium falciparum malaria","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Benzimidazole Anthelmintic","genericName":"Benzimidazole Anthelmintic","slug":"benzimidazole-anthelmintic","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Artefenomel-Ferroquine","genericName":"Artefenomel-Ferroquine","slug":"artefenomel-ferroquine","phase":"phase_2","mechanism":"Artefenomel-Ferroquine is a combination of artefenomel and ferroquine, which targets the Plasmodium falciparum parasite.","indications":["Treatment of uncomplicated Plasmodium falciparum malaria"],"catalyst":""},{"name":"Benzimidazole Anthelmintic","genericName":"Benzimidazole Anthelmintic","slug":"benzimidazole-anthelmintic","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}